“We are thrilled to share these promising results from our OKV-119 pilot study,” said Michael Klotsman, CEO of OKAVA. “Our partnership with Vivani and their cutting-edge NanoPortal platform has enabled us to make significant strides in developing a transformative solution for feline obesity and diabetes. This is a critical step towards improving the quality of life for millions of cats and providing veterinarians with more effective tools to manage these conditions.”

Vivani, the inventor of the NanoPortal™, has been instrumental in advancing this technology for veterinary applications. Their expertise in nano-scale drug delivery has facilitated the creation of drug delivery systems capable of maintaining consistent drug levels, thus enhancing therapeutic outcomes and compliance.

“Our collaboration with OKAVA exemplifies the potential of the nanoportal platform to address significant health challenges,” said [Vivani’s Representative’s Name], [Title] at Vivani. “We look forward to further advancing this partnership to bring OKV-119 to market and making a substantial impact on the management of feline obesity and diabetes.”

OKAVA is committed to advancing veterinary care through innovative biotechnological solutions. With the promising results of this pilot study, OKAVA plans to initiate further clinical trials to refine and validate OKV-119, aiming for a commercial launch that could revolutionize the treatment of chronic feline conditions.

For more details on the study and ongoing developments, please visit www.OKAVA.com or access the publication in BMC Veterinary Research ( https://rdcu.be/dIlB1).